You are hereArticles

Articles


FORMULATION AND DESIGN OF METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Goundla Uday Bhasker Goud1*, Jakkampudi Sri Venu Prakash1, Avadhanam Pranav Kumar2, Gangi Reddy Sreenivas Reddy2, Manikanta Sai Krishna2.
1Department of Industrial Pharmacy
2Department of Pharmaceutics
Bharat Institute Of Technology, Mangalpally, Hyd, Telangana, India.
gouds.uday04@gmail.com

ABSTRACT
Aim:
The current paper was an attempt to design a extended release dosage form of Metformin hydrochloride using various grades of hydrophilic polymers, hydroxy propyl methyl cellulose (HPMC K4M, HPMC K15M, HPMC K100M and HPMC K200M) and MCC.
Materials and Methods:
Laboratory scale batches of 4 tablet formulations were prepared by wet granulation technique. Precompression parameters of the granules were evaluated prior to compression. Tablets were characterized as crushing strength, friability, weight variation, thickness, drug content or assay and evaluated for in-vitro release pattern for 12 hr using Phosphate buffer of pH 6.8 at 37 ± 0.5°C.
Results and Discussion:
The results obtained revealed that HPMC K100M in formulation (F3) was able to sustain the drug release for 12 h and followed the Higuchi pattern quasi-Fickian diffusion. and charged for stability testing, parameters were within the limit of acceptance. There was no chemical interaction found between the drug and excipients during Fourier Transform Infrared Spectroscopy (FTIR).
Conclusion:
Hence it can be concluded that formulation F3 containing HPMC K100M is suitable for development of extended release tablets of Metformin Hydrochloride.


DEVELOPMENT AND VALIDATION OF SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS DETERMINATION OF SILDENAFIL CITRATE AND DAPOXETINE HYDROCHLORIDE IN THEIR COMBINED DOSAGE FORMULATION

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Chetan A. Prajapati, Bhavik S. Patel
Department of Quality Assurance, Shri Sarvajanik Pharmacy College
Nr. Arvind Baug, Mehsana, Gujarat, India
prajapatichetan25@gmail.com

ABSTRACT
A simple, accurate and precise spectrophotometric method has been developed for simultaneous estimation of Sildenafil Citrate and Dapoxetine Hydrochloride in combined dosage form. Simultaneous equation method is employed for simultaneous determination of Sildenafil Citrate and Dapoxetine Hydrochloride from combined dosage forms. In this method, the absorbance was measured at 291 nm for Sildenafil Citrate and 230nm for Dapoxetine Hydrochloride. Linearity was observed in range of 6-42μg/ml and 2-10μg/ml for Sildenafil Citrate and Dapoxetine Hydrochloride respectively. Recovery studies confirmed the accuracy of proposed method and results were validated as per ICH guidelines. The method can be used for routine quality control of pharmaceutical formulation containing Sildenafil Citrate and Dapoxetine Hydrochloride.


PHYSICISTS IN PHARMACEUTICAL INDUSTRY

{ DOWNLOAD AS PDF }

ABOUT AUTHOR
Prakash Chanda Gupta
Quality Control Executive,
National Healthcare Pvt. Ltd, Nepal
p_c_gupta@yahoo.com

ABSTRACT
The science of physics is understood to be very away from the Pharmaceutical Science. But in the real context, Physics is found to be most densely involved in the Pharmaceutical Science than any other field of science. Physics can be considered as a backbone that supports Pharmaceutical Science. The advance technology that describes that formation and its mode of action to the biological organ is Physics. The structure, action and result of Pharmaceutical material are explained by the theories of Physics.


A REVIEW ON PHARMACOLOGY OF COMBINED EDARAVONE AND ARGATROBAN THERAPY IN ACUTE ISCHEMIC STROKE

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Patel  Divya A*., Varodiya Priyanka S., Raj Hasumati A.
Department of Quality Assurance, Shree Dhanvantary Pharmacy College,
Kim, Surat, Gujarat, India
divyapatel388@gmail.com, drharaj@yahoo.com

ABSTRACT
This review article presents the pharmacology of combined edaravone and argatroban therapy especially in acute ischemic stroke. Edaravone (MCI-186) is a free radical scavenger, a novel neuroprotective agent. Argatroban  is a selective thrombin inhibitor.The antithrombotic agent was used in acute cerebral infarction. If the antithrombotic agent is administered in large quantities, the condition of patient become worse by occurrence of adeverse effect of cerebral haeorrhage. The use of edaravone in combination with antithrombotic agent has been proved to provide beneficial effect in acute ischemic stroke as edaravone has no influence to coagulation of blood and platelets aggregation. The combination therapy has fewer hemorrhagic  adeverse  effect. The mechanism of argatroban and edaravone is quite different. Argatroban, an anti-coagulant drug, directly improves the microcirculation of ischemic brain tissue while edaravone could indirectly attenuated brain edema by protection of endothelial cells damaged by free radicals generated after ischemic insult. The combination of both would have reciprocal and enhanced neuroprotective effects against ischemic insult. Both the drugs were approved by Japanese government and has been used in acute brain infarction in japan. The main objective of this review article is to provide pharmacological information of combined therapy of edaravone and argatroban to researcher in development of combined dosage form of this.


A REVIEW ON SINGLE USE DISPOSABLE TECHNOLOGY FOR RECOMBINANT PROTEIN MANUFACTURING

ABOUT AUTHOR
Madhusudan P Dabhole
Group Manager – BioProcess,
Richcore Life Sciences Ltd, Bangalore, Karnataka, India
madhav888@rediffmail.com

ABSTRACT
The manufacturing of recombinant products by fermentation and purification in stainless steel vessels has seen the transition from small scale to large scale and further to single use disposable technology. The requirement to develop and modulate the process has arisen from the cost and manufacturers need to move the facility on mobile platforms. The review describes the strategies and considerations for Single Use Disposable Technology. Recombinant proteins are widely used for treatment of various diseases and disorders. Single Use Disposable Technology makes it promising to produce and formulate these proteins from bench scale to commercial level in a shorter span of time so that it can reach the physician and patients.


HEPARIN: POWERFUL AND INSTANTANEOUSLY ACTING ANTICOAGULANT

{ DOWNLOAD AS PDF }

ABOUT AUTHOR
Amitava Sinha Ray
Ranbaxy Laboratories Ltd
West Bengal, India
a.amitava.s@gmail.com

ABSTRACT
Anticoagulantis an agent that is used to prevent the formation of blood clots. Anticoagulants, such as heparin or warfarin work on chemical reactions in the body to lengthen the time it takes to form a blood clot. Heparin the anticoagulant drug that is used to prevent blood clots from forming during and after surgery and to treat various heart, lung, and circulatory disorders in human body. Heparin is comparatively a strong acid that forms water–soluble salts. It is used in treatment of venous thrombosis and its extensions, pulmonary embolism (PE), peripheral arterial embolism. Smoking and alcohol may alter response to heparin. Abrupt withdrawal of heparin may precipitate increased coagulability.


DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR ESTIMATION OF MANIDIPINE HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORM

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Bhavik S. Patel*, Chetan A. Prajapati
Department of Quality Assurance
Pacific College of Pharmacy, Udaipur, Rajasthan, India
*bhavikpatel412@gmail.com

ABSTRACT
A novel, precise, accurate and rapid isocratic reversed-phase high performance liquid chromatographic (RP-HPLC) method was developed, optimized and validated for determination of Manidipine HCL. novel stability-indicating RP-HPLC method has been develop and validated for quantitative analysis of Manidipine HCL in in its pharmaceutical dosage forms using Column -Inertsil ODS 3v column (150 mm x 4.6 mm i.d., 5 μm)  with Phosphate buffer (pH-2.2) : Acetonitrile (60:40) as isocratic mobile phase at a flow rate of 1.4 ml/min and wavelength of 228 nm. The calibration curves were linear over the concentration ranges of 20-150 μg/ml for Manidipine HCL. The limit of detection (LOD) and limit of quantification (LOQ) for Manidipine HCL were 0.48 and 1.47 μg/ml.Recovery of Manidipine HCL the pharmaceutical dosage form ranged from 99.89-100.71%.
Manidipine HCL was subjected to stress conditions (Hydrolysis (acid, base), oxidation, thermal and photo degradation) and the stressed samples were analysed by use of the method. Degradation was observed in acid, base, and 30% H2O2.


ANTACIDS: HEART BURN OTC DRUGS

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Tribhuvan Patel*, Virendra Kr. Baheliya, Rajesh Kr. Prajapati, Vivek Kr. Yadav, Avanish Kr. Yadav, Pramod Kr. Jaiswal
Department of Pharmaceutical Sciences,
Kunwar Haribansh Singh College of Pharmacy, Jaunpur, U.P.
*vikashk464@gmail.com

ABSTRACT
Antacids are chemical substances which neutralizing the acid that causes heartburn. By reducing the acidity, the acid is less able to irritate the esophagus. The effect of antacids on the stomach is due to partial neutralisation of gastric hydrochloric acid and inhibition of the proteolytic enzyme, pepsin. There are commonly used self-prescribed medications.  Antacids are available many forms such as suspensions, chewable tablets and liquid gels. They consist of calcium carbonate and magnesium and aluminum salts in various compounds or combinations. Antacids are used for gastric and duodenal ulcers, gastro-oesophageal reflux disease, stress gastritis, pancreatic insufficiency, non-ulcer dyspepsia, biliary reflux, bile acid mediated diarrhoea, constipation, osteoporosis, urinary alkalinisation and chronic renal failure as a dietary phosphate binder.


A REVIEW ON EBOLA VIRUS DISEASE

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Rathore KS*, Roshan Keshari, Annu Rathore, Divya Chauhan
BN Institute of Pharmaceutical Sciences,
Udaipur, Rajasthan, India
kamalsrathore@gmail.com

ABSTRACT
The Ebola virus (formerly officially designated Zaire ebolavirus, or EBOV) was first seen infecting humans in African continent; especially Sudan, Democratic Republican of Congo, Zaire and nearby countries. Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus. In the current outbreak, most cases are the result of human-to-human transmission, when there is direct contact with bodily fluids, secretions, the mucous membrane or broken skin of an infected person. The disease typically occurs in outbreaks in tropical regions of Sub-Saharan Africa. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. But now, the virus seems to have enthralled the global interest due to its lethal prospective. EVD outbreaks have a case fatality rate of up to 90%. The research is ongoing on development of making vaccine to curb this virus yet licensed success or specific treatment is not achieved. Severely ill patients require intensive supportive care.


AN INSIGHT ON RAYNAUD’S DISEASE: CAUSES, SYMPTOMS, DIAGNOSIS, TREATMENT AND PREVENTION

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
*Roshan Keshari1, Sonika Shrivastava2, Rathore KS1
1BN Institute of Pharmaceutical Sciences, Udaipur-Rajasthan, India
2KD Dental College and Hospital, Mathura-UP, India
roshankeshari@gmail.com

ABSTRACT
Raynaud’s disease is illustrated by a pale to blue to red series of color changes of the digits, most commonly after exposure to cold. Raynaud’s phenomenon is a state of the flow that affects blood deliver to the skin and causes the extremities of the body to drop feeling and become numb also paroxysmal paleness and coldness of the extremities. Total 5-6% of global population is affected by this illness. Symptoms of Raynaud’s phenomenon depend on the severity, incidence, and length of the blood-vessel spasm. There is no blood test for diagnosing Raynaud’s phenomenon.

Certain Synonyms of Raynaud’s phenomenon: systemic lupus erythematosus, microcirculation and vasoconstriction. Raynaud’s disease is of two types: Primary Raynaud’s phenomenon or idiopathic is considered the more frequent, milder condition. There is no underlying disease associated with the primary classification. About 75-80% of all cases diagnosed happen in women between 15 and 40years elderly. Another is Secondary Raynaud’s phenomenon is not so frequent, but is considered the more severe of the two types. It is associated with an underlying disease, most commonly, one of the connective tissue diseases

The risk factors include: smoking, working with vibrating machinery - the fingers may go into spasm. This is due to an intermittent lack of blood supply to the fingers and emotional distress, exposure to the cold; women are affected more often than men. Management of Raynaud’s disease is possible with medical, nursing, pharmacological, and surgical way.